Table S1.
Summary of excluded references and their exclusion reasons
| Excluded references | Exclusion reason |
|---|---|
| Mehta et al1 | Full manuscript has been published |
| Fragoulakis et al2 | Full manuscript has been published |
| Wang et al3 | Full manuscript has been published |
| Wang et al4 | Full manuscript has been published |
| Wang et al5 | Full manuscript has been published |
| Wang et al6 | Full manuscript has been published |
| Popat et al7 | BTZ was not studied |
| Schey et al8 | BTZ was not studied |
| Tuffaha et al9 | BTZ was not studied |
| Gaultney et al10 | BTZ was not studied |
| Gaultney et al11 | Not CEA (cohort study for clinical outcomes) |
| Hornberger et al12 | Not CEA (cost study) |
| Teitelbaum et al13 | Not CEA (cost study) |
| Vitale et al14 | Not CEA (cost study) |
| Gaultney et al15 | Insufficient information |
| Gibbons et al16 | Insufficient information |
| Blommestein et al17 | Insufficient information |
| Durie et al18 | Outcome measures for health benefits were not LY and/or QALY |
| Gooding et al19 | Outcome measures for health benefits were not LY and/or QALY |
| Schey and Higginson20 | Review |
| Haycox and Tolley21 | Review |
| Cecchi et al22 | Letter |
| Lucioni et al23 | Non-English |
| Vandekerckhove et al24 | Not MM patients |
| Shustik et al25 | Budget impact analysis |
| Blommestein et al26 | Insufficient information |
| Gooding et al27 | Control group was lacking for the calculation of ICER |
Abbreviations: BTZ, bortezomib; CEA, cost-effectiveness analyses; LY, life year; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; MM, multiple myeloma.